LakeShore Biopharma Co., Ltd.
ysbiopharm.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 20-F, filed Jul 31, 2025. Its latest SEC filing is a SCHEDULE 13D/A from Jun 25, 2026.
20-F for FY2025, filed Jul 31, 2025
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells rabies vaccines primarily to disease-control centers in China and develops vaccines and therapeutic biologics for infectious diseases and cancer.
20-F for FY2025, filed Jul 31, 2025We are a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of…View ↗
We commercialize vaccines with significant revenue and growth potential. We take pride in our marketed vaccine product, YSJATM rabies…View ↗
LakeShore Group’s sales are made primarily to Centers for Disease Control and Prevention (“CDCs”) in China. LakeShore Group does not have a…View ↗
Who Were Their Customers?
Its sales are made primarily to Centers for Disease Control and Prevention in China.
20-F for FY2025, filed Jul 31, 2025LakeShore Group’s sales are made primarily to Centers for Disease Control and Prevention (“CDCs”) in China. LakeShore Group does not have a…View ↗
Loading...
